FDA Nominee Overton Won't Say Whether Trump Can Be Wrong

Heidi Overton, President Trump's nominee to lead the Food and Drug Administration, spent nearly two hours before the Senate Health, Education, Labor, and Pensions Committee on Sept. 24 without answering whether the president can ever be wrong, according to Ars Technica's account of the hearing. The exchange came during questioning on vaccines, flavored vapes, birth control, and abortion — the substantive issues that will define the agency she has been picked to run.

What did Overton say when asked if Trump could be wrong?

Sen. Maggie Hassan (D-NH) put the question directly: "Do you think it's possible for the president to ever be wrong about something?" Overton did not answer. She opened with, "I've had the privilege of working for the president for over a year and a half and have had robust discussions with him," according to Ars Technica's transcript of the hearing. Hassan cut her off and repeated the question twice more, including tying it to specific claims about the MMR vaccine and Tylenol during pregnancy. Overton did not say yes or no on any of those follow-ups.

Hassan later told Overton, "I wish it wasn't so difficult for members of the administration to just plainly say that the president's wrong," per the same report, adding that Overton's evasiveness was "really concerning."

Where did Overton break with Trump on vaccines — and where did she not?

Overton did contradict the president on the underlying science, even while refusing to say he was wrong. At an August press conference, Trump called the measles, mumps, and rubella (MMR) vaccine "quite lethal," claimed infant vaccine doses are "like the size of a soda bottle," and called for splitting the combined MMR shot into three separate immunizations — a version that is not available in the U.S. and for which Ars Technica reports there is no evidence of added benefit. Overton stood behind him at that event.

At the hearing, she stated plainly that "the MMR vaccine is not lethal" and that it "is safe and effective." But when Hassan asked whether that meant the president was wrong to call it lethal, Overton pivoted: "Senator, the president asks questions and wants the best outcomes for the American people right now," she said, according to Ars Technica. The pattern repeated on Tylenol: Overton said "there is no current evidence of a causal link between Tylenol and autism" — the claim Trump has made — but declined to say he was wrong to make it.

Why does the FDA's mifepristone review matter to her confirmation?

Overton has taken a public stance opposing abortion, a position Ars Technica notes raises questions about her objectivity as commissioner. The FDA is currently reviewing the safety of mifepristone, the abortion pill, even as the outlet reports that extensive existing data show the drug is extremely safe. Any FDA action on the drug's approval status or distribution rules would fall under the incoming commissioner's authority, making Overton's past advocacy a direct line of questioning for senators weighing her nomination.

What is Overton's professional background?

Overton is a physician who holds a doctoral degree in clinical investigation. She currently serves as deputy assistant to the president for domestic policy and previously worked at a conservative think tank, according to Ars Technica. That combination of a clinical credential and a policy role inside the White House is part of why senators pressed her on independence from the administration she has served for the past year and a half.

By the numbers

• Nearly 2 hours: length of Overton's questioning before the Senate HELP Committee on Sept. 24, per Ars Technica.
• 1.5 years: how long Overton says she has worked for Trump, cited in her own answer to Hassan.
• 3: the number of separate shots Trump has called for splitting the MMR vaccine into, despite no such formulation being available in the U.S.

Timeline: from the MMR remarks to the hearing

• August 2026: Trump, with Overton standing behind him, calls the MMR vaccine "quite lethal" and proposes splitting it into three shots at a press conference.
• Sept. 24, 2026: Overton testifies before the Senate HELP Committee in Washington, facing questions on vaccines, vapes, birth control, and abortion.
• Ongoing: The FDA's review of mifepristone's safety profile continues, a process the next commissioner will oversee.

The committee's confirmation timeline beyond the Sept. 24 hearing was not detailed in available reporting.

mindfulAI Keyboard — An iPhone keyboard that rewrites a draft in a tone you pick. Four free AI actions a day.